Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epstein Barr Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43894   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Epstein Barr Virus. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-000468-26 Sponsor Protocol Number: Rit EBV Start Date*: 2007-01-11
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A phase I/II multicentre study to evaluate the safety and efficacy of rituximab (monoclonal antibody anti-CD20) for prevention and/or therapy of EBV-disease.
    Medical condition: NOT AVAILABLE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015108 Epstein-Barr virus infection LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000085-42 Sponsor Protocol Number: LLB-2019-03 Start Date*: Information not available in EudraCT
    Sponsor Name:LABO'LIFE Belgium sprl
    Full Title: Randomized, placebo-controlled, double blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection. EBVAST Study
    Medical condition: Epstein-Barr Virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10014077 EBV infection LLT
    23.0 100000004862 10014078 EBV infection reactivation LLT
    21.1 100000004848 10056906 EBV antibody positive LLT
    21.0 100000004848 10056907 EBV antigen positive LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000763-45 Sponsor Protocol Number: P-105-401 Start Date*: 2022-07-25
    Sponsor Name:AlloVir, Inc.
    Full Title: Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005105-27 Sponsor Protocol Number: P-105-202 Start Date*: 2022-05-02
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV...
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000169-19 Sponsor Protocol Number: Start Date*: 2019-09-03
    Sponsor Name:Queen Mary University London
    Full Title: Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis.
    Medical condition: Epstein Barr virus infection in people with multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 100000004862 10014077 EBV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004686-28 Sponsor Protocol Number: 14143JK-AS Start Date*: 2018-07-16
    Sponsor Name:Belfast Health and Social Care Trust (BHSCT)
    Full Title: A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial).
    Medical condition: Epstein-Barr virus infection in patients with chronic obstructive pulmonary disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000853-29 Sponsor Protocol Number: TRACE Start Date*: 2020-01-14
    Sponsor Name:Klinikum der Universität München
    Full Title: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
    Medical condition: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10067859 Allogenic stem cell transplantation PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) ES (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000177-25 Sponsor Protocol Number: ATA129-EBV-205 Start Date*: 2021-01-04
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
    Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002795-13 Sponsor Protocol Number: TACRO-Omics Start Date*: 2020-04-23
    Sponsor Name:Fundación de Investigación Hospital Universitario La Paz
    Full Title: Identification of "omic" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients...
    Medical condition: Pediatric patients with renal transplantation (under stable treatment with tacrolimus as immunosuppressant)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005197-10 Sponsor Protocol Number: VT3996-202 Start Date*: 2021-10-01
    Sponsor Name:Viracta Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
    Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071441 Epstein-Barr virus associated lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000252-28 Sponsor Protocol Number: SHCVOLT1 Start Date*: 2009-03-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...
    Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052779 Transplant rejections HLT
    9.1 10024970 Respiratory tract infections HLGT
    9.1 10046577 Urinary tract infections HLT
    9.1 10001032 Acute pyelonephritis LLT
    9.1 10040072 Septicaemia LLT
    9.1 10019972 Herpes viral infections HLT
    9.1 10028440 Mycobacterial infectious disorders HLGT
    9.1 10015107 Epstein-Barr viral infections HLT
    9.1 10011831 Cytomegalovirus infection LLT
    9.1 10019974 Herpes zoster LLT
    9.1 10058872 Fungal sepsis LLT
    9.1 10040808 Skin cancer PT
    9.1 10051358 Post transplant lymphoproliferative disorder LLT
    9.1 10043555 Thrombocytopenias HLT
    9.1 10037561 Purpura thrombocytopenic LLT
    9.1 10002034 Anaemia PT
    9.1 10018932 Haemolytic uraemic syndrome PT
    9.1 10024384 Leukopenia PT
    9.1 10029355 Neutropenias HLT
    9.1 10033661 Pancytopenia PT
    9.1 10013505 Disturbance of liver function tests LLT
    9.1 10002218 Anaphylaxis LLT
    9.1 10002425 Angioedemas HLT
    9.1 10015665 Exfoliative dermatitis LLT
    9.1 10020764 Hypersensitivity vasculitis LLT
    9.1 10021015 Hypokalaemia PT
    9.1 10021058 Hypophosphataemia PT
    9.1 10020603 Hypercholesterolaemia PT
    9.1 10020635 Hyperglycaemia PT
    9.1 10020869 Hypertriglyceridaemia PT
    9.1 10043071 Tachycardia PT
    9.1 10034474 Pericardial effusion PT
    9.1 10048642 Lymphocele PT
    9.1 10051055 Deep vein thrombosis PT
    9.1 10037377 Pulmonary embolism PT
    9.1 10025282 Lymphoedema PT
    9.1 10035742 Pneumonitis PT
    9.1 10035598 Pleural effusion PT
    9.1 10015090 Epistaxis PT
    9.1 10037394 Pulmonary haemorrhage PT
    9.1 10000081 Abdominal pain PT
    9.1 10012735 Diarrhoea PT
    9.1 10042128 Stomatitis PT
    9.1 10033645 Pancreatitis PT
    9.1 10000496 Acne PT
    9.1 10037844 Rash PT
    9.1 10003239 Arthralgia PT
    9.1 10031264 Osteonecrosis PT
    9.1 10037032 Proteinuria PT
    9.1 10029164 Nephrotic syndrome PT
    9.1 10030124 Oedema peripheral PT
    9.1 10021519 Impaired healing PT
    9.1 10030095 Oedema PT
    9.1 10037660 Pyrexia PT
    9.1 10005630 Blood lactate dehydrogenase increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005150-28 Sponsor Protocol Number: PTC:VS-TC Start Date*: 2022-07-25
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation(HSCT)
    Medical condition: Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10056559 Graft infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000722-26 Sponsor Protocol Number: AVM-003-HC Start Date*: 2021-01-11
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans...
    Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10059348 Viral hemorrhagic cystitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000168-31 Sponsor Protocol Number: M20-621 Start Date*: 2022-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) DE (Ongoing) GR (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing) AT (Trial now transitioned) SK (Trial now transitioned) BG (Ongoing) HR (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015162-57 Sponsor Protocol Number: P06153 Start Date*: 2011-03-02
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) SE (Prematurely Ended) BG (Completed) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001157-23 Sponsor Protocol Number: GO44096 Start Date*: 2023-01-03
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS FIXED-DOSE COMBINATION (IV FDC) OF TIRAGOLUMAB AND ATEZOLIZUMAB IN PARTICIPANTS WITH LOCALLY A...
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) CY (Trial now transitioned) ES (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004689-11 Sponsor Protocol Number: MOR208C204 Start Date*: 2016-05-24
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who ...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) DE (Ongoing) FI (Ongoing) PT (Ongoing) FR (Ongoing) AT (Completed) CZ (Ongoing) ES (Ongoing) RO (Ongoing) GB (GB - no longer in EU/EEA) HR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002563-25 Sponsor Protocol Number: VEGF-RTX-2013 Start Date*: 2014-01-13
    Sponsor Name:VU University Medical Centre
    Full Title: Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma
    Medical condition: Angiogenesis in esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10015362 Esophageal cancer LLT
    20.0 100000004864 10030151 Oesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004240-30 Sponsor Protocol Number: AIT-MULTIVIR-01 Start Date*: 2014-06-18
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-sp...
    Medical condition: Immune deficiency after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10007877 Cell-mediated immune deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 15:32:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA